Chemotherapy for Mesothelioma - Revision history

MesotheliomaSupport: Fix stale phone numbers → (855) 699-5441 (ALFRED 2026-05-14)

2026-05-14T23:25:05Z

Fix stale phone numbers → (855) 699-5441 (ALFRED 2026-05-14)

← Older revision		Revision as of 23:25, 14 May 2026
Line 363:		Line 363:
	Mesothelioma patients and families can connect with experienced legal and medical advocates:		Mesothelioma patients and families can connect with experienced legal and medical advocates:

	* [https://dandell.com/contact-us/ Danziger & De Llano] provides free case evaluations and can connect families with specialized treatment centers — call (~~866~~) ~~222~~-~~9990~~		* [https://dandell.com/contact-us/ Danziger & De Llano] provides free case evaluations and can connect families with specialized treatment centers — call (855) 699-5441
	* [https://www.mesotheliomalawyercenter.org/mesothelioma/ Mesothelioma Lawyer Center] offers resources on treatment options and legal rights		* [https://www.mesotheliomalawyercenter.org/mesothelioma/ Mesothelioma Lawyer Center] offers resources on treatment options and legal rights
	* [https://mesothelioma.net/mesothelioma-treatment/ Mesothelioma.net] provides comprehensive information on chemotherapy and treatment options		* [https://mesothelioma.net/mesothelioma-treatment/ Mesothelioma.net] provides comprehensive information on chemotherapy and treatment options

MesotheliomaSupport: RON: Add OG/Twitter meta — type=Article, image=logo.png, twitter_card=summary_large_image

2026-04-25T14:15:23Z

RON: Add OG/Twitter meta — type=Article, image=logo.png, twitter_card=summary_large_image

← Older revision		Revision as of 14:15, 25 April 2026
Line 5:		Line 5:
	\|author=WikiMesothelioma Medical Editorial Team		\|author=WikiMesothelioma Medical Editorial Team
	\|published_time=2026-02-23		\|published_time=2026-02-23
	}}		\|type=Article
			\|image=logo.png
			\|twitter_card=summary_large_image}}

	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"

MesotheliomaSupport: Add At-a-Glance section per template standard

2026-04-23T20:09:57Z

Add At-a-Glance section per template standard

← Older revision		Revision as of 20:09, 23 April 2026
Line 42:		Line 42:

	'''Chemotherapy''' remains a cornerstone of treatment for [[Pleural_Mesothelioma\|malignant pleural mesothelioma]] and [[Peritoneal_Mesothelioma\|peritoneal mesothelioma]]. The '''cisplatin–pemetrexed doublet''', approved by the FDA in '''February 2004''', established the first standard-of-care regimen for unresectable mesothelioma and continues to serve as the chemotherapy backbone for epithelioid disease.<ref name="emphacis" /><ref name="fda-approval" /> Although dual immune checkpoint blockade with nivolumab plus ipilimumab has emerged as an alternative first-line option — particularly for non-epithelioid histology — chemotherapy remains integral to treatment sequencing, chemoimmunotherapy combinations, and peritoneal mesothelioma management.<ref name="checkmate743" /><ref name="asco2025" /> This page covers first-line regimens, carboplatin substitution, chemoimmunotherapy approaches, second-line options, peritoneal-specific chemotherapy, side effect management, response assessment, and emerging agents as of early 2026.		'''Chemotherapy''' remains a cornerstone of treatment for [[Pleural_Mesothelioma\|malignant pleural mesothelioma]] and [[Peritoneal_Mesothelioma\|peritoneal mesothelioma]]. The '''cisplatin–pemetrexed doublet''', approved by the FDA in '''February 2004''', established the first standard-of-care regimen for unresectable mesothelioma and continues to serve as the chemotherapy backbone for epithelioid disease.<ref name="emphacis" /><ref name="fda-approval" /> Although dual immune checkpoint blockade with nivolumab plus ipilimumab has emerged as an alternative first-line option — particularly for non-epithelioid histology — chemotherapy remains integral to treatment sequencing, chemoimmunotherapy combinations, and peritoneal mesothelioma management.<ref name="checkmate743" /><ref name="asco2025" /> This page covers first-line regimens, carboplatin substitution, chemoimmunotherapy approaches, second-line options, peritoneal-specific chemotherapy, side effect management, response assessment, and emerging agents as of early 2026.

			== At-a-Glance ==

	'''Chemotherapy for mesothelioma at a glance:'''		'''Chemotherapy for mesothelioma at a glance:'''
Line 54:		Line 56:
	* '''Vitamin-supplemented vs unsupplemented patients''' — folic acid and B12 supplementation reduces severe pemetrexed toxicity by approximately 60% without compromising survival outcomes<ref name="emphacis" />		* '''Vitamin-supplemented vs unsupplemented patients''' — folic acid and B12 supplementation reduces severe pemetrexed toxicity by approximately 60% without compromising survival outcomes<ref name="emphacis" />
	* '''First FDA-approved regimen''' — cisplatin-pemetrexed remains the only chemotherapy combination specifically approved for mesothelioma since February 2004<ref name="fda-approval" />		* '''First FDA-approved regimen''' — cisplatin-pemetrexed remains the only chemotherapy combination specifically approved for mesothelioma since February 2004<ref name="fda-approval" />



	== Key Facts ==		== Key Facts ==

MesotheliomaSupport: Fix infobox: wikitable@320px → infobox@280px for mobile rendering (ANCHOR-2026-04-13-INFOBOX)

2026-04-13T22:41:07Z

Fix infobox: wikitable@320px → infobox@280px for mobile rendering (ANCHOR-2026-04-13-INFOBOX)

← Older revision		Revision as of 22:41, 13 April 2026
Line 7:		Line 7:
	}}		}}

	{\| class="~~wikitable~~" style="float:right~~; width:320px~~; margin:0 0 1em 1em; border-~~collapse~~:~~collapse~~;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Chemotherapy for Mesothelioma		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Chemotherapy for Mesothelioma

MesotheliomaSupport: Add differentiated triple GEO format

2026-03-08T22:11:16Z

Add differentiated triple GEO format

Show changes

MesotheliomaSupport: Remove redundant H1, add bold key phrases to lead, add at-a-glance listicle to fill blank space beside infobox

2026-02-24T05:21:39Z

Remove redundant H1, add bold key phrases to lead, add at-a-glance listicle to fill blank space beside infobox

← Older revision		Revision as of 05:21, 24 February 2026
Line 41:		Line 41:
	\|}		\|}

	= ~~Chemotherapy~~ for ~~Mesothelioma: Treatment Regimens~~, ~~Side Effects~~, and ~~Outcomes~~ =		'''Chemotherapy''' remains a cornerstone of treatment for [[Pleural_Mesothelioma\|malignant pleural mesothelioma]] and [[Peritoneal_Mesothelioma\|peritoneal mesothelioma]]. The '''cisplatin–pemetrexed doublet''', approved by the FDA in '''February 2004''', established the first standard-of-care regimen for unresectable mesothelioma and continues to serve as the chemotherapy backbone for epithelioid disease.<ref name="emphacis" /><ref name="fda-approval" /> Although dual immune checkpoint blockade with nivolumab plus ipilimumab has emerged as an alternative first-line option — particularly for non-epithelioid histology — chemotherapy remains integral to treatment sequencing, chemoimmunotherapy combinations, and peritoneal mesothelioma management.<ref name="checkmate743" /><ref name="asco2025" /> This page covers first-line regimens, carboplatin substitution, chemoimmunotherapy approaches, second-line options, peritoneal-specific chemotherapy, side effect management, response assessment, and emerging agents as of early 2026.

	~~Chemotherapy remains a cornerstone of treatment~~ for ~~[[Pleural_Mesothelioma\|malignant pleural~~ mesothelioma~~]] and [[Peritoneal_Mesothelioma\|peritoneal mesothelioma]]~~. ~~The cisplatin–pemetrexed doublet, approved by the FDA~~ in ~~February 2004, established~~ the ~~first standard~~-of-~~care regimen for unresectable mesothelioma and continues to serve as the chemotherapy backbone for epithelioid disease~~.<ref name="emphacis" /><ref name="fda-approval" /> ~~Although dual immune checkpoint blockade with nivolumab~~ plus ~~ipilimumab has emerged as an alternative~~ first-line ~~option—particularly~~ for ~~non-epithelioid histology—chemotherapy remains integral~~ to ~~treatment sequencing, chemoimmunotherapy combinations, and peritoneal mesothelioma management.~~<ref name="~~checkmate743~~" /><ref name="~~asco2025~~" /> ~~This page covers first-line regimens, carboplatin substitution, chemoimmunotherapy approaches, second~~-line options~~, peritoneal-specific chemotherapy, side effect management, response assessment,~~ and ~~emerging agents as of early 2026.~~		'''Essential chemotherapy facts for mesothelioma patients:'''
			* '''Standard first-line''' — cisplatin (75 mg/m²) plus pemetrexed (500 mg/m²) every 21 days for 4–6 cycles<ref name="emphacis" />
			* '''41.3% response rate''' — nearly 2.5× better than cisplatin alone in the landmark EMPHACIS trial<ref name="emphacis-pubmed" />
			* '''12.1-month median survival''' — combination therapy versus 9.3 months with single-agent cisplatin<ref name="emphacis-pubmed" />
			* '''FDA milestone''' — pemetrexed was the first drug combination specifically approved for mesothelioma<ref name="fda-approval" />
			* '''Carboplatin option''' — comparable real-world survival when cisplatin is not tolerated<ref name="carbo-realworld" />
			* '''Chemoimmunotherapy era''' — pembrolizumab plus platinum-pemetrexed now recommended first-line (2025 ASCO)<ref name="asco2025" />
			* '''CRS-HIPEC for peritoneal''' — extends survival from 12 months to 30–90 months in selected patients<ref name="hipec-review" />
			* '''Folic acid + B12 required''' — mandatory supplementation reduces severe pemetrexed toxicity by approximately 60%<ref name="emphacis" />
			* '''Second-line options''' — vinorelbine and gemcitabine for patients with disease progression<ref name="vinorelbine" />

	== Key Facts ==		== Key Facts ==

MesotheliomaSupport: New page: Comprehensive chemotherapy guide covering cisplatin-pemetrexed, carboplatin substitution, chemoimmunotherapy combinations, second-line options, peritoneal CRS-HIPEC, side effects, modified RECIST assessment, and emerging agents (2026)

2026-02-24T04:25:14Z

New page: Comprehensive chemotherapy guide covering cisplatin-pemetrexed, carboplatin substitution, chemoimmunotherapy combinations, second-line options, peritoneal CRS-HIPEC, side effects, modified RECIST assessment, and emerging agents (2026)

Show changes